Capricor Therapeutics (CAPR) Competitors $18.60 -0.86 (-4.42%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CAPR vs. LPTX, CLSD, PRPH, EYEN, NRBO, FOLD, RYTM, EWTX, HCM, and XENEShould you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Leap Therapeutics (LPTX), Clearside Biomedical (CLSD), ProPhase Labs (PRPH), Eyenovia (EYEN), NeuroBo Pharmaceuticals (NRBO), Amicus Therapeutics (FOLD), Rhythm Pharmaceuticals (RYTM), Edgewise Therapeutics (EWTX), HUTCHMED (HCM), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry. Capricor Therapeutics vs. Leap Therapeutics Clearside Biomedical ProPhase Labs Eyenovia NeuroBo Pharmaceuticals Amicus Therapeutics Rhythm Pharmaceuticals Edgewise Therapeutics HUTCHMED Xenon Pharmaceuticals Leap Therapeutics (NASDAQ:LPTX) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings. Does the media favor LPTX or CAPR? In the previous week, Capricor Therapeutics had 4 more articles in the media than Leap Therapeutics. MarketBeat recorded 4 mentions for Capricor Therapeutics and 0 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 1.11 beat Capricor Therapeutics' score of 0.21 indicating that Leap Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Leap Therapeutics Positive Capricor Therapeutics Neutral Is LPTX or CAPR more profitable? Leap Therapeutics has a net margin of 0.00% compared to Capricor Therapeutics' net margin of -102.93%. Leap Therapeutics' return on equity of -98.01% beat Capricor Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Leap TherapeuticsN/A -98.01% -81.43% Capricor Therapeutics -102.93%-220.27%-60.88% Do analysts prefer LPTX or CAPR? Leap Therapeutics presently has a consensus target price of $10.40, indicating a potential upside of 183.38%. Capricor Therapeutics has a consensus target price of $24.67, indicating a potential upside of 32.65%. Given Leap Therapeutics' higher probable upside, equities research analysts clearly believe Leap Therapeutics is more favorable than Capricor Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leap Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Capricor Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of LPTX or CAPR? 30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 5.4% of Leap Therapeutics shares are owned by insiders. Comparatively, 12.0% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, LPTX or CAPR? Leap Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 3.99, indicating that its stock price is 299% more volatile than the S&P 500. Which has stronger earnings & valuation, LPTX or CAPR? Capricor Therapeutics has higher revenue and earnings than Leap Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeap Therapeutics$1.50M62.63-$81.41M-$2.00-1.84Capricor Therapeutics$25.18M33.53-$22.29M-$0.93-19.99 Does the MarketBeat Community favor LPTX or CAPR? Capricor Therapeutics received 63 more outperform votes than Leap Therapeutics when rated by MarketBeat users. However, 68.87% of users gave Leap Therapeutics an outperform vote while only 63.39% of users gave Capricor Therapeutics an outperform vote. CompanyUnderperformOutperformLeap TherapeuticsOutperform Votes29268.87% Underperform Votes13231.13% Capricor TherapeuticsOutperform Votes35563.39% Underperform Votes20536.61% SummaryCapricor Therapeutics beats Leap Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPR vs. The Competition Export to ExcelMetricCapricor TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$844.40M$6.79B$5.11B$8.43BDividend YieldN/A7.94%7.56%4.16%P/E Ratio-19.9912.50126.1616.71Price / Sales33.53270.991,651.6576.32Price / CashN/A46.0937.4133.56Price / Book25.475.274.614.98Net Income-$22.29M$152.08M$116.32M$224.69M7 Day Performance-15.44%-2.23%-0.96%-0.51%1 Month Performance-14.11%14.00%5.36%3.32%1 Year Performance547.91%36.66%33.86%25.51% Capricor Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPRCapricor Therapeutics3.3989 of 5 stars$18.60-4.4%$24.67+32.7%+547.7%$883.15M$25.18M-19.99N/AUpcoming EarningsLPTXLeap Therapeutics2.8797 of 5 stars$3.67-1.9%$10.40+183.4%+102.8%$93.95M$1.50M-1.8440Upcoming EarningsPositive NewsCLSDClearside Biomedical2.8062 of 5 stars$1.03+2.0%$5.17+401.6%+7.8%$76.97M$8.23M-2.0630Upcoming EarningsPRPHProPhase Labs3.0408 of 5 stars$2.19+2.3%$11.00+402.3%-51.8%$41.78M$17.97M-1.81130Positive NewsGap UpEYENEyenovia2.8851 of 5 stars$0.52+2.0%$12.00+2,216.2%-63.8%$33.19MN/A-0.6540Upcoming EarningsNRBONeuroBo Pharmaceuticals2.7933 of 5 stars$2.53-5.2%$10.00+295.3%-24.7%$20.80MN/A0.008Upcoming EarningsNews CoverageGap DownFOLDAmicus Therapeutics4.3439 of 5 stars$11.33-1.2%$17.13+51.1%-2.2%$3.36B$455.66M-29.05480Upcoming EarningsRYTMRhythm Pharmaceuticals3.6096 of 5 stars$52.99+8.1%$60.33+13.9%+96.5%$3.24B$77.43M-12.15140EWTXEdgewise Therapeutics1.9734 of 5 stars$34.48+1.4%$35.60+3.2%+411.6%$3.23BN/A-22.2560Positive NewsHCMHUTCHMED1.0849 of 5 stars$18.38-1.3%$20.55+11.8%-6.7%$3.20B$838M0.001,988Analyst UpgradeXENEXenon Pharmaceuticals3.5496 of 5 stars$41.71+0.0%$57.45+37.7%+26.9%$3.16B$9.43M-15.22251Positive News Related Companies and Tools Related Companies LPTX Competitors CLSD Competitors PRPH Competitors EYEN Competitors NRBO Competitors FOLD Competitors RYTM Competitors EWTX Competitors HCM Competitors XENE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CAPR) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CAPR Stock Alerts